Biotech & Life Sciences
-
Retevmo Delivers Clinically Meaningful Event‑Free Survival in Phase 3 Trial
Eli Lilly and Company (NYSE:LLY) announced positive topline results from its Phase 3 LIBRETTO‑432 trial, evaluating Retevmo (selpercatinib) as adjuvant therapy in patients with early‑stage RET fusion‑positive non‑small cell lung cancer (NSCLC). The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in event‑free survival compared to placebo. Trial highlights Overall…
-
Hands‑Free AI Reading Now Live in U.S. Radiology Practices
Coreline Soft has partnered with INFINITT North America to embed its AVIEW AI platform directly into the INFINITT PACS environment. The result is a fully automated, zero‑click AI reading solution now live in U.S. radiology practices. Radiologists can access AI‑powered insights without extra logins or workflow interruptions, making advanced technology part of everyday clinical practice.…
-
St. Luke’s Rolls Out Secure Cloud Imaging Archive With Sectra
St. Luke’s University Health Network has rolled out a new enterprise imaging solution from Sectra. Instead of juggling different systems, all images now flow into one secure archive. Radiology, cardiology, ophthalmology, and other specialties feed into the same platform, making it easier for caregivers to pull up studies instantly no matter where they were created.…
-
FDA Clears ArkBio to Begin U.S. Trial of Anti‑Fibrotic AK3280
Strategic Clinical Milestone Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept clinical trial in the United States, marking a…
-
Deloitte Research Highlights Growing Divide in Health Care AI Adoption
Deloitte LLP has released new research showing a growing divide in health care between early adopters of agentic AI and more cautious organizations. The report indicates that 85% of health care leaders plan to increase investment in agentic AI over the next two to three years, with 61% already building or implementing initiatives. Adoption Challenges…
-
Hospital Adoption Targeted With Sky Labs’ CART ON Ring Device
Sky Labs has launched CART ON, a hospital ward solution that uses a ring-type wearable to continuously measure and manage inpatient blood pressure. The release marks the company’s expansion from outpatient and consumer monitoring into inpatient care, targeting one of the most workflow-intensive areas of hospital operations. For investors and healthcare operators, the move signals…
-
Pulsenmore Validates U.S. Market Demand With New Maternal‑Fetal Partnership
Home Ultrasound Gains Traction Among U.S. Maternal-Fetal Medicine Practices Pulsenmore has secured another commercial engagement in the United States, continuing to build momentum following recent FDA clearance of its home ultrasound technology. The latest agreement brings Pulsenmore’s Early Screening home ultrasound services into TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice operating in…
-
Innovent and Lilly Launch Breakthrough $8.5B Global Drug Collaboration
Innovent Biologics has entered into a new strategic collaboration with Eli Lilly aimed at developing next-generation medicines for cancer and immune-related diseases, deepening a partnership that has spanned more than a decade. The agreement represents the seventh collaboration between the two companies and introduces a development model designed to accelerate Innovent’s pipeline from early discovery…
-
Azitra Extends Timeline as Shareholder Meeting Reconvenes in Early March
AZTR performance by TradingView Azitra, Inc. (NYSE AMERICAN: AZTR) has adjourned its recently convened special shareholder meeting after failing to reach the minimum quorum required to proceed with voting. The meeting is now scheduled to reconvene on March 6, 2026, giving the company additional time to solicit shareholder participation on key corporate proposals. At the…
-
10x Genomics Partners with PharosAI to Build Breakthrough AI‑Ready Cancer Datasets
TXG performance by TradingView Strategic Partnership Announcement 10x Genomics, Inc. (Nasdaq: TXG) announced that PharosAI, a UK research consortium, will use its Xenium spatial platform to create one of the world’s most comprehensive multimodal cancer datasets. Backed by £18.9 million from the UK Government’s Research Ventures Catalyst and additional support from charities and industry partners,…
